Altimmune, Inc. (NASDAQ: ALT)

Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, operates in the healthcare sector, specifically focusing on developing treatments for obesity and liver diseases. The company's main business activities involve the research, development, and commercialization of innovative therapeutics. Altimmune operates primarily in the United States, with additional operations in the United Kingdom and South Korea, where it conducts clinical trials for its product candidates.

The company generates revenue primarily from the development of its lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist designed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MAAS). Pemvidutide works by reducing appetite and inflammation, while increasing energy expenditure, adipose browning, and mobilization of liver fat. Altimmune has completed Phase 1 and Phase 1b clinical trials for pemvidutide, which have demonstrated significant weight loss and improvements in metabolic and lipid profiles in overweight and obese volunteers and subjects with MAAS, respectively.

Altimmune holds a competitive advantage within the industry due to its focus on developing treatments for underserved obesity and liver disease markets. The company's proprietary platform technologies, such as its EuPort and Densigen platforms, allow for the development of more effective and efficient treatments compared to existing therapies. Key competitors within the obesity and liver disease markets include established pharmaceutical companies like Eli Lilly, Roche, Novo Nordisk, Pfizer, AstraZeneca, Amgen, and Merck.

While the text provided does not include specific customer names, Altimmune's customers primarily consist of pharmaceutical companies and research institutions interested in developing and commercializing new treatments for obesity and liver diseases. Altimmune's products are designed for use in various settings, including clinical trials, research institutions, and commercial markets.

Altimmune's lead product, pemvidutide, is a promising treatment for obesity and MAAS, with significant weight loss and improvements in metabolic and lipid profiles observed in clinical trials. Additionally, the company is developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). HepTcell is designed to drive CD4+ and CD8+ T-cell responses against all HBV genotypes in patients of all ethnic backgrounds.